<i>In vitro</i>and<i>in vivo</i>antitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor

Wang, Zhiping; Wu, Jinglei; Chen, Tongsheng; Zhou, Qun; Wang, Yifei

doi:10.1117/12.2079107

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this investigation, we first studied the effect of Ber-SLN on H22 tumor to assess if SLN could enhance Ber anti-cancer effects. The present study showed that Ber reduced tumor weight in H22 tumor-bearing mice, which were consistent with other studies [25] . The therapeutic effects of Ber-SLN were obviously improved when prepared with SLN.…”

Section: Conclusion and Discussionsupporting

confidence: 94%

In Vitro and in Vivo Antitumor Efficacy of Berberine-solid Lipid Nanoparticles Against H22 Tumor

Meng¹,

Wang²,

Wang³

2016

Proceedings of the 2016 6th International Conference on Applied Science, Engineering and Technology

Self Cite

View full text Add to dashboard Cite

Hepatocarcinoma, a malignant cancer, threaten human life badly. It is a current issue to seek the effective natural remedy from plant to treat cancer due to the resistance of the advanced hepatocarcinoma to chemotherapy. Berberine (Ber), an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-hepatocarcinoma effects. However its low oral bioavailability restricts its wide application. In this report, Ber loaded solid lipid nanoparticles (Ber-SLN) was prepared by hot melting and then high pressure homogenization technique. Both in vitro and in vivo anti-hepatocarcinoma effects of Ber-SLN relative to efficacy of bulk Ber were evaluated. The particle size and zeta potential of Ber-SLN were 154.2 ± 0.8 nm and −18.63±0.99mV, respectively. MTT assay showed that Ber-SLN effectively inhibited the proliferation of H22 cells, and the corresponding IC 50 values were 11.6 µg/ml (18.3 µg/ml of bulk Ber). In vivo studies also showed higher antitumor efficacy, and inhibition rates was 65.1% (41.4 % of bulk Ber) at 100mg/kg intragastric administration in H22 solid tumor bearing mice. These results suggest that the delivery of Ber-SLN is a promising approach for treating tumors.

show abstract

Section: Conclusion and Discussionsupporting

confidence: 94%

In Vitro and in Vivo Antitumor Efficacy of Berberine-solid Lipid Nanoparticles Against H22 Tumor

Meng¹,

Wang²,

Wang³

2016

Proceedings of the 2016 6th International Conference on Applied Science, Engineering and Technology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this respect, Meng et al designed BBR-loaded NLCs and found that BBR-NLC efficiently reduced the development of HepG2, Huh7, and EC9706 malignant cells of humans in vitro and also demonstrated that the potential of NLCs to improve the effectiveness of BBR was likely mainly due to increased bioavailability and blood levels [155]. Wang et al prepared BBR-loaded NLCs and observed that BBR-NLCs considerably reduced H22 cell proliferation in vitro and showed significant anticancer action in in vivo models with respect to bulk BBR solution [156].…”

Section: Nanostructured Lipid Carriersmentioning

confidence: 99%

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends

et al. 2022

View full text Add to dashboard Cite

Traditionally, herbal compounds have been the focus of scientific interest for the last several centuries, and continuous research into their medicinal potential is underway. Berberine (BBR) is an isoquinoline alkaloid extracted from plants that possess a broad array of medicinal properties, including anti-diarrheal, anti-fibrotic, antidiabetic, anti-inflammatory, anti-obesity, antihyperlipidemic, antihypertensive, antiarrhythmic, antidepressant, and anxiolytic effects, and is frequently utilized as a traditional Chinese medicine. BBR promotes metabolisms of glucose and lipids by activating adenosine monophosphate-activated protein kinase, stimulating glycolysis and inhibiting functions of mitochondria; all of these ameliorate type 2 diabetes mellitus. BBR has also been shown to have benefits in congestive heart failure, hypercholesterolemia, atherosclerosis, non-alcoholic fatty liver disease, Alzheimer’s disease, and polycystic ovary syndrome. BBR has been investigated as an interesting pharmacophore with the potential to contribute significantly to the research and development of novel therapeutic medicines for a variety of disorders. Despite its enormous therapeutic promise, the clinical application of this alkaloid was severely limited because of its unpleasant pharmacokinetic characteristics. Poor bioavailability, limited absorption, and poor water solubility are some of the obstacles that restricted its use. Nanotechnology has been suggested as a possible solution to these problems. The present review aims at recent updates on important therapeutic activities of BBR and different types of nanocarriers used for the delivery of BBR in different diseases.

show abstract

“…In addition, varieties of nanoparticle carriers have been discovered and used to enhance solubility and Berberine’s bioavailability. For example, nanostructured lipid carriers (NLCs) [ 137 , 138 ], micelles [ 139 ], and other lipid-based nanoparticles were shown to enhance oral bioavailability, solubility, and therapeutic outcome via Berberine’s encapsulation. Similarly, dendrimers [ 140 ], nanogels [ 141 ], chitosan [ 142 ], and all other polymeric-based nanoparticle carriers were also shown to improve Berberine’s pharmacokinetics.…”

Section: Limitations and Future Perspectivementioning

confidence: 99%

Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment

Achi

Sarbadhikary

George

et al. 2022

Cells

View full text Add to dashboard Cite

Despite therapeutic advancements, lung cancer remains the principal cause of cancer mortality in a global scenario. The increased incidence of tumor reoccurrence and progression and the highly metastatic nature of lung cancer are of great concern and hence require the investigation of novel therapies and/or medications. Naturally occurring compounds from plants serve as important resources for novel drugs for cancer therapy. Amongst these phytochemicals, Berberine, an alkaloid, has been extensively explored as a potential natural anticancer therapeutic agent. Several studies have shown the effectiveness of Berberine in inhibiting cancer growth and progression mediated via several different mechanisms, which include cell cycle arrest, inducing cell death by apoptosis and autophagy, inhibiting cell proliferation and invasion, as well as regulating the expression of microRNA, telomerase activity, and the tumor microenvironment, which usually varies for different cancer types. In this review, we aim to provide a better understanding of molecular insights of Berberine and its various derivative-induced antiproliferative and antimetastatic effects against lung cancer. In conclusion, the Berberine imparts its anticancer efficacy against lung cancers via modulation of several signaling pathways involved in cancer cell viability and proliferation, as well as migration, invasion, and metastasis.

show abstract

In vitroandin vivoantitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor

Cited by 6 publications

References 24 publications

In Vitro and in Vivo Antitumor Efficacy of Berberine-solid Lipid Nanoparticles Against H22 Tumor

In Vitro and in Vivo Antitumor Efficacy of Berberine-solid Lipid Nanoparticles Against H22 Tumor

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends

Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment

Contact Info

Product

Resources

About